Literature DB >> 30611739

Dual role of twist1 in cancer-associated fibroblasts and tumor cells promoted epithelial-mesenchymal transition of esophageal cancer.

Xiaoming Zhu1, Shuangyin Han2, Sen Wu1, Yangqiu Bai1, Ning Zhang1, Li Wei3.   

Abstract

Cancer-associated fibroblasts (CAFs) play critical roles in tumor progression. However, the role and mechanism underlying CAFs in esophageal cancer (EC) remain unclear. In this study, primary CAFs and normal esophageal fibroblasts (NOFs) were isolated and characterized by immunofluorescence, qRT-PCR and western blot. Clinical significance of twist1 in CAFs were evaluated by immunohistochemistry assay. Conditioned medium (CM) was collected from CAFs to evaluate the influence on epithelial-mesenchymal transition (EMT) of EC cells. EC cells were mixed with CAFs and subcutaneously injected into nude mice to assess the in vivo tumor growth. As the result, twist1 was overexpressed in CAFs compared with NOFs and exhibited adverse prognostic significance. In CAFs, twist1 promoted the expression and secretion of CXCL12. In EC cells, activated CXCL12/CXCR4 signaling promoted the EMT process through ERK/AKT - twist1 - MMP1/E-cadherin pathway. In addition, knockdown of twist1 in CAFs also suppressed in vivo tumor growth. In conclusion, our results revealed a dual role of twist1 in CAFs and EC cells to promote the EMT process.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer-associated fibroblasts; Epithelial-mesenchymal transition; Esophageal cancer; Twist1

Mesh:

Substances:

Year:  2019        PMID: 30611739     DOI: 10.1016/j.yexcr.2019.01.002

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  Overexpressed PKMYT1 promotes tumor progression and associates with poor survival in esophageal squamous cell carcinoma.

Authors:  Qingyi Zhang; Xuan Zhao; Chaoqi Zhang; Wei Wang; Feng Li; Donglei Liu; Kai Wu; Dengyan Zhu; Shasha Liu; Chunyi Shen; Xin Yuan; Kai Zhang; Yang Yang; Yi Zhang; Song Zhao
Journal:  Cancer Manag Res       Date:  2019-08-19       Impact factor: 3.989

2.  Pin2 telomeric repeat factor 1-interacting telomerase inhibitor 1 (PinX1) inhibits nasopharyngeal cancer cell stemness: implication for cancer progression and therapeutic targeting.

Authors:  Chaosheng Yu; Fang Chen; Xiaoqi Wang; Zhimou Cai; Mengxue Yang; Qingwen Zhong; Jialian Feng; Junzheng Li; Congxiang Shen; Zhong Wen
Journal:  J Exp Clin Cancer Res       Date:  2020-02-07

Review 3.  Could gastrointestinal tumor-initiating cells originate from cell-cell fusion in vivo?

Authors:  Yang Zhou; Jun-Ting Cheng; Zi-Xian Feng; Ying-Ying Wang; Ying Zhang; Wen-Qi Cai; Zi-Wen Han; Xian-Wang Wang; Ying Xiang; Hui-Yu Yang; Bing-Rong Liu; Xiao-Chun Peng; Shu-Zhong Cui; Hong-Wu Xin
Journal:  World J Gastrointest Oncol       Date:  2021-02-15

4.  Cancer-Associated Fibroblasts Promote Migration and Invasion of Non-Small Cell Lung Cancer Cells via miR-101-3p Mediated VEGFA Secretion and AKT/eNOS Pathway.

Authors:  Xueru Guo; Mengmeng Chen; Limin Cao; Yiming Hu; Xueqin Li; Qicheng Zhang; Yinghui Ren; Xiang Wu; Zhaowei Meng; Ke Xu
Journal:  Front Cell Dev Biol       Date:  2021-12-16

Review 5.  Cytokine Interaction With Cancer-Associated Fibroblasts in Esophageal Cancer.

Authors:  Md Sazzad Hassan; Nicholas Cwidak; Niranjan Awasthi; Urs von Holzen
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

Review 6.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10

7.  EphA5 knockdown enhances the invasion and migration ability of esophageal squamous cell carcinoma via epithelial-mesenchymal transition through activating Wnt/β-catenin pathway.

Authors:  Rui Zhang; Jing Liu; Wei Zhang; Lei Hua; Li-Ting Qian; Shao-Bing Zhou
Journal:  Cancer Cell Int       Date:  2020-01-13       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.